News | January 25, 2022
USFDA rejects Merck’s gefapixant; gain approval in Japan
Merck is studying the Complete Response Letter and it is not related to the safety of gefapixant
Merck is studying the Complete Response Letter and it is not related to the safety of gefapixant
Studies show significant reduction in pain and improved quality of life for patients treated with spinal cord stimulation compared to medication management alone
The six-layer packaging ensures that external media such as bacteria, light and air do not contaminate the liquid
APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types
Madhavbaug has a pan-India presence with a vast network of 272 clinics and two hospitals
Pfizer is evaluating the FDA’s comments and will work with the agency to determine an appropriate path forward
It is the first CAR T Therapy approved for the treatment of multiple myeloma in Japan
Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumours
Quviviq is a dual orexin receptor antagonist, which blocks the binding of the wake-promoting neuropeptides orexins and is thought to turn down overactive wakefulness, as opposed to treatments that generally sedate the brain
Ram’s appointment follows the launch of the CDI India division in October 2021.
Subscribe To Our Newsletter & Stay Updated
